385 related articles for article (PubMed ID: 29568909)
1. Hyperthermia inhibits the motility of gemcitabine-resistant pancreatic cancer PANC-1 cells through the inhibition of epithelial-mesenchymal transition.
Jin H; Zhao Y; Zhang S; Yang J; Zhang X; Ma S
Mol Med Rep; 2018 May; 17(5):7274-7280. PubMed ID: 29568909
[TBL] [Abstract][Full Text] [Related]
2. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
[TBL] [Abstract][Full Text] [Related]
3. Modulated Electro-Hyperthermia Supports the Effect of Gemcitabine Both in Sensitive and Resistant Pancreas Adenocarcinoma Cell Lines.
Forika G; Kiss E; Petovari G; Danko T; Gellert AB; Krenacs T
Pathol Oncol Res; 2021; 27():1610048. PubMed ID: 34955688
[TBL] [Abstract][Full Text] [Related]
4. Effects of obatoclax combined with gemcitabine on the biological activity of pancreatic cancer cells under hypoxic conditions.
Hou XF; Li S; Wu C; Li K; Xu SN; Wang JF
Mol Med Rep; 2018 Jul; 18(1):495-501. PubMed ID: 29749486
[TBL] [Abstract][Full Text] [Related]
5. IFN‑γ induces apoptosis in gemcitabine‑resistant pancreatic cancer cells.
Kong X; Cheng D; Xu X; Zhang Y; Li X; Pan W
Mol Med Rep; 2024 May; 29(5):. PubMed ID: 38488034
[TBL] [Abstract][Full Text] [Related]
6. The effects of novel chitosan-targeted gemcitabine nanomedicine mediating cisplatin on epithelial mesenchymal transition, invasion and metastasis of pancreatic cancer cells.
Yu H; Song H; Xiao J; Chen H; Jin X; Lin X; Pan B; Ji W
Biomed Pharmacother; 2017 Dec; 96():650-658. PubMed ID: 29035831
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.
Ma J; Fang B; Zeng F; Ma C; Pang H; Cheng L; Shi Y; Wang H; Yin B; Xia J; Wang Z
Oncotarget; 2015 Jan; 6(3):1740-9. PubMed ID: 25638153
[TBL] [Abstract][Full Text] [Related]
8. MGMT expression affects the gemcitabine resistance of pancreatic cancer cells.
Shi Y; Wang Y; Qian J; Yan X; Han Y; Yao N; Ma J
Life Sci; 2020 Oct; 259():118148. PubMed ID: 32721465
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine resistance is associated with epithelial-mesenchymal transition and induction of HIF-1α in pancreatic cancer cells.
Wang R; Cheng L; Xia J; Wang Z; Wu Q; Wang Z
Curr Cancer Drug Targets; 2014; 14(4):407-17. PubMed ID: 24575976
[TBL] [Abstract][Full Text] [Related]
10. Epigallocatechin-3-Gallate (EGCG) Suppresses Pancreatic Cancer Cell Growth, Invasion, and Migration partly through the Inhibition of Akt Pathway and Epithelial-Mesenchymal Transition: Enhanced Efficacy when Combined with Gemcitabine.
Wei R; Penso NEC; Hackman RM; Wang Y; Mackenzie GG
Nutrients; 2019 Aug; 11(8):. PubMed ID: 31405071
[TBL] [Abstract][Full Text] [Related]
11. E3 ubiquitin ligase UBR5 promotes gemcitabine resistance in pancreatic cancer by inducing O-GlcNAcylation-mediated EMT via destabilization of OGA.
Du Y; Yang Z; Shi H; Chen Z; Chen R; Zhou F; Peng X; Hong T; Jiang L
Cell Death Dis; 2024 May; 15(5):340. PubMed ID: 38755129
[TBL] [Abstract][Full Text] [Related]
12. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
[TBL] [Abstract][Full Text] [Related]
13. HDAC inhibitors, trichostatin A and valproic acid, increase E‑cadherin and vimentin expression but inhibit migration and invasion of cholangiocarcinoma cells.
Wang JH; Lee EJ; Ji M; Park SM
Oncol Rep; 2018 Jul; 40(1):346-354. PubMed ID: 29767267
[TBL] [Abstract][Full Text] [Related]
14. Catechol enhances chemo‑ and radio‑sensitivity by targeting AMPK/Hippo signaling in pancreatic cancer cells.
Moon JY; Ediriweera MK; Ryu JY; Kim HY; Cho SK
Oncol Rep; 2021 Mar; 45(3):1133-1141. PubMed ID: 33650657
[TBL] [Abstract][Full Text] [Related]
15. Naringenin decreases invasiveness and metastasis by inhibiting TGF-β-induced epithelial to mesenchymal transition in pancreatic cancer cells.
Lou C; Zhang F; Yang M; Zhao J; Zeng W; Fang X; Zhang Y; Zhang C; Liang W
PLoS One; 2012; 7(12):e50956. PubMed ID: 23300530
[TBL] [Abstract][Full Text] [Related]
16. Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape.
Lee JE; Kang YW; Jung KH; Son MK; Shin SM; Kim JS; Kim SJ; Fang Z; Yan HH; Park JH; Yoon YC; Han B; Cheon MJ; Woo MG; Seo MS; Lim JH; Kim YS; Hong SS
Cancer Lett; 2021 Jun; 507():97-111. PubMed ID: 33744388
[TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide sensitizes pancreatic cancer cells to gemcitabine through downregulation of the TIMP1/PI3K/AKT/mTOR axis.
Tian Z; Tan Y; Lin X; Su M; Pan L; Lin L; Ou G; Chen Y
Transl Res; 2023 May; 255():66-76. PubMed ID: 36400307
[TBL] [Abstract][Full Text] [Related]
18. Paracrine HGF promotes EMT and mediates the effects of PSC on chemoresistance by activating c-Met/PI3K/Akt signaling in pancreatic cancer in vitro.
Xu J; Liu S; Yang X; Cao S; Zhou Y
Life Sci; 2020 Dec; 263():118523. PubMed ID: 33039386
[TBL] [Abstract][Full Text] [Related]
19. miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn.
Liu G; Ji L; Ke M; Ou Z; Tang N; Li Y
Biomed Pharmacother; 2018 Oct; 106():523-531. PubMed ID: 29990840
[TBL] [Abstract][Full Text] [Related]
20. The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer.
Pan MR; Hsu MC; Luo CW; Chen LT; Shan YS; Hung WC
Oncotarget; 2016 Sep; 7(38):61136-61151. PubMed ID: 27531902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
